Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × nintedanib × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Melanoma, Cutaneous Malignant 1 Glioblastoma 1 Colonic Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Temozolomide 69 Radiotherapy 30 Bevacizumab 24 Carboplatin 13 pembrolizumab 12 Radiation 11 Carmustine 8 Irinotecan 7 temsirolimus 6 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 atezolizumab 5 Vorinostat 5 Sirolimus 5 Radiotherapy, Intensity-Modulated 5 Nivolumab 5 Lomustine 5 Everolimus 5 fludarabine 4 Radiotherapy, Conformal 4 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 Aminolevulinic Acid 4 tipifarnib 3 Sorafenib 3 Paclitaxel 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01666600 2017-11-01

NOA-12: BIBF1120 and R-RT in Glioblastoma

University Hospital Heidelberg

Phase 1/2 Terminated

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡